You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR ORENCIA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ORENCIA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00035529 ↗ A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis Terminated Bristol-Myers Squibb Phase 2 2001-11-01 The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
NCT00048581 ↗ Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. Completed Bristol-Myers Squibb Phase 3 2002-12-01 The purpose of this clinical research study is to determine whether abatacept treatment on a background of Disease Modifying Antirheumatic Drugs (DMARDs) will relieve the symptoms of rheumatoid arthritis (RA) in participants who are currently receiving anti-tumor necrosis factor (TNF) therapy for at least 3 months and are not responding or have taken anti-TNF therapy in the last 3 months and did not respond. The safety of treatment with abatacept will also be evaluated. This study also has a 4.5-year long-term extension beginning 6 months after the start of the study.
NCT00048932 ↗ A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis Completed Bristol-Myers Squibb Phase 3 2002-12-01 The purpose of this clinical research study is to learn if abatacept is safe when co-administered with other approved rheumatoid arthritis medications.
NCT00095147 ↗ Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis Completed Bristol-Myers Squibb Phase 3 2005-02-01 The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.
NCT00095173 ↗ BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis Completed Bristol-Myers Squibb Phase 3 2003-12-01 The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare.
NCT00119678 ↗ Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone Completed Bristol-Myers Squibb Phase 2 2005-09-01 The purpose of this clinical research study is to learn whether Abatacept can treat and prevent lupus flares; specifically, in patients with active lupus flares in at least one of three organ systems: skin (discoid lesions); inflammation of the lining of the heart (pericarditis), or inflammation of the lining of the lung (pleuritis/pleurisy); or inflammation of more than 4 joints (arthritis). All participants will receive prednisone or prednisone-equivalent treatment in combination with study medication. The safety of this treatment will also be studied.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ORENCIA

Condition Name

Condition Name for ORENCIA
Intervention Trials
Rheumatoid Arthritis 38
Rheumatoid Arthritis (RA) 4
Psoriatic Arthritis 3
Arthritis, Rheumatoid 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ORENCIA
Intervention Trials
Arthritis 52
Arthritis, Rheumatoid 48
Graft vs Host Disease 6
Lupus Erythematosus, Systemic 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ORENCIA

Trials by Country

Trials by Country for ORENCIA
Location Trials
United States 525
Mexico 67
Canada 60
Brazil 44
Australia 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ORENCIA
Location Trials
New York 29
Pennsylvania 27
Massachusetts 27
California 27
Ohio 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ORENCIA

Clinical Trial Phase

Clinical Trial Phase for ORENCIA
Clinical Trial Phase Trials
Phase 4 16
Phase 3 26
Phase 2/Phase 3 1
[disabled in preview] 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ORENCIA
Clinical Trial Phase Trials
Completed 49
Recruiting 21
Terminated 10
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ORENCIA

Sponsor Name

Sponsor Name for ORENCIA
Sponsor Trials
Bristol-Myers Squibb 67
Emory University 5
Boston Children's Hospital 3
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ORENCIA
Sponsor Trials
Other 93
Industry 74
NIH 9
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.